Clinical Trials

    MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

    Investigator: Siddhartha Ganguly

    Study Coordinator: Danielle Sewall

    Status: Enrolling

    ClinicalTrials.gov Number: NCT06152575

    Phone: 346.238.2674

    Protocol Number: PRO00037922

    Description


    The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer).